Bardini Gianluca, Rotella Carlo M, Giannini Stefano
Section of Endocrinology, Department of Clinical Pathophysiology, University of Florence, Italy.
Rev Diabet Stud. 2012 Summer-Fall;9(2-3):82-93. doi: 10.1900/RDS.2012.9.82. Epub 2012 Nov 15.
Patients with diabetes frequently exhibit the combined occurrence of hyperglycemia and dyslipidemia. Published data on their coexistence are often controversial. Some studies provide evidence for suboptimal lifestyle and exogenous hyperinsulinism at "mild insulin resistance" in adult diabetic patients as main pathogenic factors. In contrast, other studies confirm that visceral adiposity and insulin resistance are the basic features of dyslipidemia in type 2 diabetes (T2D). The consequence is an excess of free fatty acids, which causes hepatic gluconeogenesis to increase, metabolism in muscles to shift from glucose to lipid, beta-cell lipotoxicity, and an appearance of the classical "lipid triad", without real hypercholesterolemia. Recently, it has been proposed that cholesterol homeostasis is important for an adequate insulin secretory performance of beta-cells. The accumulation of cholesterol in beta-cells, caused by defective high-density lipoprotein (HDL) cholesterol with reduced cholesterol efflux, induces hyperglycemia, impaired insulin secretion, and beta-cell apoptosis. Data from animal models and humans, including humans with Tangier disease, who are characterized by very low HDL cholesterol levels, are frequently associated with hyperglycemia and T2D. Thus, there is a reciprocal influence of dyslipidemia on beta-cell function and inversely of beta-cell dysfunction on lipid metabolism and micro- and macrovascular complications. It remains to be clarified how these different but mutually influencing adverse effects act in together to define measures for a more effective prevention and treatment of micro- and macrovascular complications in diabetes patients. While the control of circulating low-density lipoprotein (LDL) cholesterol and the level of HDL cholesterol are determinant targets for the reduction of cardiovascular risk, based on recent data, these targets should also be considered for the prevention of beta-cell dysfunction and the development of type 2 diabetes. In this review, we analyze consolidated data and recent advances on the relationship between lipid metabolism and diabetes mellitus, with particular attention to the reciprocal effects of the two features of the disease and the development of vascular complications.
糖尿病患者常常同时出现高血糖和血脂异常。关于它们共存的已发表数据往往存在争议。一些研究表明,成年糖尿病患者在“轻度胰岛素抵抗”时不良的生活方式和外源性高胰岛素血症是主要致病因素。相反,其他研究证实内脏肥胖和胰岛素抵抗是2型糖尿病(T2D)血脂异常的基本特征。其结果是游离脂肪酸过多,导致肝糖异生增加,肌肉代谢从葡萄糖转向脂质,β细胞脂毒性,并出现典型的“脂质三联征”,但并无真正的高胆固醇血症。最近,有人提出胆固醇稳态对β细胞充分的胰岛素分泌功能很重要。高密度脂蛋白(HDL)胆固醇缺陷导致胆固醇流出减少,进而使胆固醇在β细胞中蓄积,诱发高血糖、胰岛素分泌受损和β细胞凋亡。来自动物模型和人类的数据,包括患有丹吉尔病(其特征为HDL胆固醇水平极低)的人类,常常与高血糖和T2D相关。因此,血脂异常对β细胞功能有相互影响,反之,β细胞功能障碍对脂质代谢以及微血管和大血管并发症也有相互影响。这些不同但相互影响的不良反应如何共同作用以确定更有效地预防和治疗糖尿病患者微血管和大血管并发症的措施仍有待阐明。虽然控制循环中的低密度脂蛋白(LDL)胆固醇和HDL胆固醇水平是降低心血管风险的决定性目标,但根据最近的数据,这些目标也应考虑用于预防β细胞功能障碍和2型糖尿病的发生。在本综述中,我们分析了脂质代谢与糖尿病之间关系的综合数据和最新进展,特别关注该疾病两个特征之间的相互作用以及血管并发症的发展。